Celiac Disease Clinical Trial
Official title:
Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting
The purpose of this study is to determine if patients with unexplained iron deficiency have
underlying diseases processes such as celiac disease.
It is hypothesized that selectively screening patients with unexplained iron deficiency will
reveal previously undiagnosed etiologies, including celiac disease and other causes of iron
malabsorption along with various sources of occult GI blood loss.
The primary purpose of the study is to document unexplained iron deficiency and its
relationship to celiac disease, iron malabsorption and occult intestinal blood loss. Test
results given to primary care physicians may prompt further testing for celiac disease
(duodenal biopsy) or other potential causes of occult iron deficiency. The specific
endpoints to be evaluated include:
- Prevalence of specific serum markers of celiac disease in those with unexplained serum
markers of iron deficiency.
- Prevalence of iron malabsorption with and without celiac disease in the same population
- Frequency of other blood tests for malabsorption and their association with celiac
disease or other cause of iron malabsorption.
- Frequency of specific historical markers associated with celiac disease
- Prevalence of unrecognized GI blood loss
- Quality of life improvement based on new diagnoses with appropriate therapy
- After one year follow-up, review patient records for additional diagnoses explaining
iron deficiency.
Primary Objective:
Discover several etiologies of unexplained iron deficiency in a primary care clinic
population including celiac disease, iron malabsorption and occult intestinal blood loss.
Secondary Objectives:
- Define percent of total clinic patient population with one or more markers of iron
deficiency on last testing and the subset without an apparent etiology on their problem
list ("study group").
- Define percent of patients in the study group that are currently iron deficient at time
of study onset, and how many of those are actually anemic.
- Define percent of study group patients with iron malabsorption, with or without celiac
disease.
- Document improved quality of life outcomes for those with new diagnoses and appropriate
therapy, including celiac disease given gluten-free diet and iron therapy.
- For those patients identified with celiac disease, do statistical analysis of
historical and lab parameters that are more highly linked to celiac disease to improve
screening parameters.
- Document percent of various diagnoses that explain occult iron deficiency as found by
primary care providers over the course of a one year follow-up after initial diagnosis.
(Providers will be given all testing results related to their patients after the
initial screening and at one year.)
- Specific cost-effectiveness of this screening procedure may be done in a future study
if preliminary results are suggestive of improved outcomes.
;
Observational Model: Cohort
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04349904 -
Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
|
||
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT05810441 -
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
|
||
Recruiting |
NCT05555446 -
Bovine Colostrum to Prevent Absorption of Gluten
|
Early Phase 1 | |
Completed |
NCT02754609 -
Hookworm Therapy for Coeliac Disease
|
Phase 1 | |
Terminated |
NCT01902368 -
Celiac Disease Screening
|
N/A | |
Completed |
NCT02312349 -
Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
|
||
Completed |
NCT02472704 -
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
|
N/A | |
Completed |
NCT01172665 -
Celiac Disease Database
|
||
Completed |
NCT01100099 -
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00639444 -
Risk of Celiac Disease and Age at Gluten Introduction
|
N/A | |
Active, not recruiting |
NCT05425446 -
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
|
Phase 1 | |
Enrolling by invitation |
NCT02202681 -
Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
|
N/A | |
Completed |
NCT00362856 -
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
|
Phase 2 | |
Terminated |
NCT03866538 -
Budesonide in Patients With Immune Mediated Enteropathies
|
Phase 4 | |
Recruiting |
NCT05135923 -
Glutenfree, Gut Microbiota and Metabolic Regulation
|
N/A | |
Completed |
NCT05052164 -
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
|
N/A | |
Completed |
NCT03775499 -
Probiotic BL NCC 2705 and Gluten Sensitivity
|
N/A | |
Completed |
NCT03707730 -
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
|
Phase 2 |